Bar Harbor, ME and Berkeley, CA — Caribou Biosciences, Inc. and The Jackson Laboratory (JAX) announced an agreement today whereby Caribou has granted JAX non-exclusive worldwide rights to use its CRISPR-Cas9 intellectual property to create genetically engineered mice for research purposes.

Caribou’s market-leading CRISPR-Cas9 technology accurately targets and cuts DNA to produce precise and controllable changes to the genome. This agreement further strengthens JAX’s leadership in applying gene editing technology to create mouse models that better recapitulate human diseases enabling researchers to find better treatments faster.

“JAX is excited to reach this CRISPR-Cas9 IP agreement with Caribou,” said Edison Liu, M.D., president and CEO of JAX. “CRISPR technology has transformed genetic engineering in nearly all biological systems. This license allows us to deliver custom-built mouse models, creating the next generation of predictive models for the new era of personalized medicine.”

“W